Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On November 26, 2021, AnaptysBio, Inc. (the "Company") appointed Mr. Daniel
Faga, as a Class I director on its board of directors (the "Board"), effective
immediately.
In connection with his appointment as a non-employee director of the Board, and
in accordance with the Company's existing compensation policy for non-employee
directors, Mr. Faga received a stock option to purchase 2,321 shares of common
stock at an exercise price equal to the closing sale price of the common stock
on November 26, 2021, as reported by the Nasdaq Global Market, which shall vest
in full on February 10, 2022, representing a pro rata portion of the annual
retainer for service as a director for the remaining portion of the year. In
addition, the Board granted to Mr. Faga, a stock option to purchase 11,000
shares of common stock at an exercise price equal to the closing sale price of
the common stock on November 26, 2021, as reported by the Nasdaq Global Market,
which will vest monthly over three years, subject to Mr. Faga's continued
service to the Company.
The Company has entered into its standard form of indemnification agreement with
Mr. Faga. The form of the indemnification agreement was previously filed by the
Company as Exhibit 10.1 to the Company's Registration Statement on Form S-1
filed with the Securities and Exchange Commission on September 9, 2015 and
incorporated by reference herein.
There are no arrangements or understandings between Mr. Faga and any other
persons, pursuant to which Mr. Faga was selected as a member of the Board. There
are also no family relationships among any of the Company's other directors or
executive officers and Mr. Faga, and Mr. Faga does not have any direct or
indirect material interest in any transaction required to be disclosed pursuant
to Item 404(a) of Regulation S-K.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
ANAPTYSBIO, INC. 
